Clinical Trial Resource Center


Therapeutic Areas: Oncology | Hematology

Hematologic Neoplasms Clinical Trials


A listing of Hematologic Neoplasms medical research trials actively recruiting patient volunteers. Click on the closest city to find more detailed information on a research study in your area.

California

Duarte : City of Hope

A Phase 2 clinical study for patients with Hematologic Malignancies

Duarte : City of Hope National Medical Center Dept.ofCityofHopeMedicalCtr(1)

A Phase 2 clinical study for patients with Hematologic Neoplasms

Palo Alto :

A clinical trial to evaluate treatments using KB004, Monoclonal Antibody for patients

Connecticut

New Haven : Yale Comprehensive Cancer Center at Yale University School of Medicine

A clinical research study for the treatment of Hematologic Malignancies

Florida

Miami :

A clinical trial to evaluate treatments using KB004, Monoclonal Antibody for patients

Sarasota : TG Therapeutics Trial Site

A clinical trial to evaluate treatments using TGR-1202 for patients with Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia or Peripheral T-Cell Lymphoma

Tampa :

A clinical trial to evaluate treatments using KB004, Monoclonal Antibody for patients

Georgia

Atlanta : Emory University-Winship Cancer Institute

A Phase 2 clinical study for patients with Hematologic Malignancies

Augusta : Georgia Regents University SC-2

A Phase 2 clinical study for patients with Hematologic Neoplasms

Indiana

Indianapolis : IU

Patients are needed to participate in a clinical research study evaluating TG02 citrate

Maryland

Baltimore : The Sidney Kimmel Comprehensive Cancer Center

A Phase 1 clinical study for patients with Hematologic Neoplasms

Massachusetts

Boston : Tufts-New England Medical Center

A clinical research study for the treatment of Hematologic Malignancies

Boston : Dana Farber Cancer Institute

A Phase 1 clinical study for patients with Hematologic Neoplasms

Boston : Boston Children's Hospital

A Phase 2 clinical study for patients with Hematologic Malignancies

Boston : Massachusetts General Hospital

A Phase 2 clinical study for patients with Hematologic Malignancies

Boston : Dana-Farber Cancer Institute- Hematopoietic Stem Cell Transplant Program

A Phase 2 clinical study for patients with Hematologic Malignancies

Boston : Dana Farber Cancer Institute SC-8

A Phase 2 clinical study for patients with Hematologic Neoplasms

Michigan

Ann Arbor : University of Michigan

A Phase 2 clinical study for patients with Hematologic Malignancies

Detroit : Karmanos Cancer Institute

Patients are needed to participate in a clinical research study of Carfilzomib to evaluate Solid Tumors, Hematologic Malignancies or Hepatic Impairment

Missouri

St. Louis : Washington University School of Medicine

A Phase 2 clinical study for patients with Hematologic Malignancies

New Jersey

Hackensack : TG Therapeutics Trial Site

A clinical trial to evaluate treatments using TGR-1202 for patients with Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia or Peripheral T-Cell Lymphoma

Hackensack : HUMC

Patients are needed to participate in a clinical research study evaluating TG02 citrate

New York

New York : TG Therapeutics Trial Site

A clinical trial to evaluate treatments using TGR-1202 for patients with Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia or Peripheral T-Cell Lymphoma

New York : Mount Sinai Hospital

A Phase 2 clinical study for patients with Hematologic Malignancies

North Carolina

Durham : TG Therapeutics Trial Site

A clinical trial to evaluate treatments using TGR-1202 for patients with Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia or Peripheral T-Cell Lymphoma

Durham : Duke Cancer Institute

Patients are needed to participate in a clinical research study of Carfilzomib to evaluate Solid Tumors, Hematologic Malignancies or Hepatic Impairment

Ohio

Canton : Gabrail Cancer Center

Patients are needed to participate in a clinical research study of Carfilzomib to evaluate Solid Tumors, Hematologic Malignancies or Hepatic Impairment

Cleveland :

A clinical trial to evaluate treatments using KB004, Monoclonal Antibody for patients

Columbus : Ohio State University Comprehensive Cancer Center

A Phase 2 clinical study for patients with Hematologic Malignancies

Columbus : OSU

Patients are needed to participate in a clinical research study evaluating TG02 citrate

Oregon

Bend : Bend Memorial Clinic Bend Mem. Clinic

Patients are needed to participate in a clinical research study of BGJ398 to evaluate Solid Tumor or Hematologic Malignancies (FGFR)

Portland : Oregon Health & Science University

A Phase 1 clinical study for patients with Hematologic Neoplasms

Portland : Oregon Health Sciences

A Phase 2 clinical study for patients with Hematologic Malignancies

Tennessee

Nashville : TG Therapeutics Trial Site

A clinical trial to evaluate treatments using TGR-1202 for patients with Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia or Peripheral T-Cell Lymphoma

Nashville : SCRI

Patients are needed to participate in a clinical research study evaluating TG02 citrate

Nashville : Sarah Cannon Cancer Center

Patients are needed to participate in a clinical research study of 120 mg LY2784544 to evaluate Neoplasms, Hematologic

Nashville : Tennessee Oncology PLLC

Patients are needed to participate in a clinical research study of 120 mg LY2784544 to evaluate Neoplasms, Hematologic

Nashville : Tennessee Oncology, PLLC

Patients are needed to participate in a clinical research study of Carfilzomib to evaluate Solid Tumors, Hematologic Malignancies or Hepatic Impairment

Texas

Houston :

A clinical trial to evaluate treatments using KB004, Monoclonal Antibody for patients

Houston : The University Of Texas Md Anderson Cancer Center

A Phase 1 clinical study for patients with Hematologic Neoplasms

San Antonio : Methodist Hospital - Texas Transplant Institute

A clinical research study for the treatment of Hematologic Malignancies

Washington

Seattle : Seattle Cancer Care Alliance

A Phase 1 clinical study for patients with Hematologic Neoplasms

Spokane : Evergreen Hematology and Oncology

Patients are needed to participate in a clinical research study of Carfilzomib to evaluate Solid Tumors, Hematologic Malignancies or Hepatic Impairment

Wisconsin

Milwaukee : TG Therapeutics Investigational Trial Site

A clinical trial to evaluate treatments using TGR-1202 for patients with Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia or Peripheral T-Cell Lymphoma

Australia

Adelaide :

A clinical trial to evaluate treatments using KB004, Monoclonal Antibody for patients

Prahran :

A clinical trial to evaluate treatments using KB004, Monoclonal Antibody for patients

Queensland :

A clinical trial to evaluate treatments using KB004, Monoclonal Antibody for patients

Westmead :

A clinical trial to evaluate treatments using KB004, Monoclonal Antibody for patients

Canada

France

Lille : CHRU Lille

Patients are needed to participate in a clinical research study of OTX015 to evaluate Acute Leukemia or Other Hematological Malignacies

Lyon : Centre Hospitalier Lyon Sud

A clinical research study of mPEG-r-crisantaspase for the treatment of Hematologic Malignancies

Paris : Hopital Saint Louis

Patients are needed to participate in a clinical research study of OTX015 to evaluate Acute Leukemia or Other Hematological Malignacies

Villejuif : Gustave Roussy

A clinical research study of Crizotinib for the treatment of Hematologic Cancers, Solid Tumors or Metastatic Cancer

Germany

Ahaus : Facharzt für Innere Medizin, Onkologie, Hämatologie

Patients are needed to participate in a clinical research study to evaluate Solid Tumor, Malignant Hematological Tumor or Primary or Secondary Prophylactic Treatment

Bad Sackingen : "Facharzt für Innere Medizin

Patients are needed to participate in a clinical research study to evaluate Solid Tumor, Malignant Hematological Tumor or Primary or Secondary Prophylactic Treatment

Berlin : MediOnko-Institut GbR

Patients are needed to participate in a clinical research study to evaluate Solid Tumor, Malignant Hematological Tumor or Primary or Secondary Prophylactic Treatment

Berlin : Onkoplan GmbH/Onkologische Schwerpunkpraxis

Patients are needed to participate in a clinical research study to evaluate Solid Tumor, Malignant Hematological Tumor or Primary or Secondary Prophylactic Treatment

Chemnitz : FA f. Frauenheilkunde und Geburtshilfe Gynakolgische Onkologie

Patients are needed to participate in a clinical research study to evaluate Solid Tumor, Malignant Hematological Tumor or Primary or Secondary Prophylactic Treatment

Dortmund : Gesellschaft für onkologische Studien Dortmund mbH

Patients are needed to participate in a clinical research study to evaluate Solid Tumor, Malignant Hematological Tumor or Primary or Secondary Prophylactic Treatment

Dresden : Gemeinschaftspraxis

Patients are needed to participate in a clinical research study to evaluate Solid Tumor, Malignant Hematological Tumor or Primary or Secondary Prophylactic Treatment

Dusseldorf : Gemeinschaftspraxis Haematologie/Medizin Onkologie

Patients are needed to participate in a clinical research study to evaluate Solid Tumor, Malignant Hematological Tumor or Primary or Secondary Prophylactic Treatment

Garbsen : Internist - Hämatologe - Onkologe

Patients are needed to participate in a clinical research study to evaluate Solid Tumor, Malignant Hematological Tumor or Primary or Secondary Prophylactic Treatment

Gutersloh : Onkodok GmbH

Patients are needed to participate in a clinical research study to evaluate Solid Tumor, Malignant Hematological Tumor or Primary or Secondary Prophylactic Treatment

Hannover : Internist - Hämatologe - Onkologe

Patients are needed to participate in a clinical research study to evaluate Solid Tumor, Malignant Hematological Tumor or Primary or Secondary Prophylactic Treatment

Heidenheim : ODZ-Petersen GmbH

Patients are needed to participate in a clinical research study to evaluate Solid Tumor, Malignant Hematological Tumor or Primary or Secondary Prophylactic Treatment

Herne : DOKUSAN Gesellschaft für medizinische Studien mbH & Co. KG

Patients are needed to participate in a clinical research study to evaluate Solid Tumor, Malignant Hematological Tumor or Primary or Secondary Prophylactic Treatment

Krefeld : ZAGO

Patients are needed to participate in a clinical research study to evaluate Solid Tumor, Malignant Hematological Tumor or Primary or Secondary Prophylactic Treatment

Leipzig : Pneumologisch/onkologisch/internistisches Studienzentrum

Patients are needed to participate in a clinical research study to evaluate Solid Tumor, Malignant Hematological Tumor or Primary or Secondary Prophylactic Treatment

Lepzig : FA f. Frauenheilkunde und Geburtshilfe

Patients are needed to participate in a clinical research study to evaluate Solid Tumor, Malignant Hematological Tumor or Primary or Secondary Prophylactic Treatment

Lippstadt : Fachübergreifende Gemeinschaftspraxis Innere Medizin, Hämatologie, Onkologie, Tumortherapie, Palliativmedizin

Patients are needed to participate in a clinical research study to evaluate Solid Tumor, Malignant Hematological Tumor or Primary or Secondary Prophylactic Treatment

Mainz : Praxis für Innere Medizin, Hämatologie und Onkologie

Patients are needed to participate in a clinical research study to evaluate Solid Tumor, Malignant Hematological Tumor or Primary or Secondary Prophylactic Treatment

Minden : Johannes Esling Klinikum Minden

Patients are needed to participate in a clinical research study to evaluate Solid Tumor, Malignant Hematological Tumor or Primary or Secondary Prophylactic Treatment

Moers : OnkoLog Moers GbR

Patients are needed to participate in a clinical research study to evaluate Solid Tumor, Malignant Hematological Tumor or Primary or Secondary Prophylactic Treatment

Munchen : Fachärzte für Innere Medizin - Hämatologie u. Internistische Onkologie - Bluttransfusionswesen

Patients are needed to participate in a clinical research study to evaluate Solid Tumor, Malignant Hematological Tumor or Primary or Secondary Prophylactic Treatment

Munchen : Forschungs- und Studiengesellschaft HOPE München GmbH

Patients are needed to participate in a clinical research study to evaluate Solid Tumor, Malignant Hematological Tumor or Primary or Secondary Prophylactic Treatment

Neustadt/Sachsen : Facharzt für Innere Medizin - Medikamentöse Tumortherapie - Palliativmedizin

Patients are needed to participate in a clinical research study to evaluate Solid Tumor, Malignant Hematological Tumor or Primary or Secondary Prophylactic Treatment

Nordhausen : MVZ Nordhausen gGmbH/ FA für Frauenheilkunde und Geburtshilfe

Patients are needed to participate in a clinical research study to evaluate Solid Tumor, Malignant Hematological Tumor or Primary or Secondary Prophylactic Treatment

Nurnberg : Martha-Maria Krankenhaus gGmbH MVZ Onkologie

Patients are needed to participate in a clinical research study to evaluate Solid Tumor, Malignant Hematological Tumor or Primary or Secondary Prophylactic Treatment

Oeide : Fachärztin für Innere Medizin Hämatologie u. Internistische Onkologie

Patients are needed to participate in a clinical research study to evaluate Solid Tumor, Malignant Hematological Tumor or Primary or Secondary Prophylactic Treatment

Olpe : Medizinisches Versorgungszentrum Onkologische Schwerpunktpraxis

Patients are needed to participate in a clinical research study to evaluate Solid Tumor, Malignant Hematological Tumor or Primary or Secondary Prophylactic Treatment

Osnabruck :

Patients are needed to participate in a clinical research study to evaluate Solid Tumor, Malignant Hematological Tumor or Primary or Secondary Prophylactic Treatment

Paradiese : Medizinisches Versorgungszentrum GbR

Patients are needed to participate in a clinical research study to evaluate Solid Tumor, Malignant Hematological Tumor or Primary or Secondary Prophylactic Treatment

Remscheid : Facharzt für Innere Medizin - Hämatologie - Onkologie - Medikamentöse Tumortherapie

Patients are needed to participate in a clinical research study to evaluate Solid Tumor, Malignant Hematological Tumor or Primary or Secondary Prophylactic Treatment

Rodgau : Frauenärzte -Naturheilverfahren-

Patients are needed to participate in a clinical research study to evaluate Solid Tumor, Malignant Hematological Tumor or Primary or Secondary Prophylactic Treatment

Siegburg : Onkol. Managementgesellschaft Bonn/Rhein-Sieg/Ahr mbH

Patients are needed to participate in a clinical research study to evaluate Solid Tumor, Malignant Hematological Tumor or Primary or Secondary Prophylactic Treatment

Stralsund : g.SUND Gyn. Kompetenzzentrum FA f. Frauenheilkunde & Geburtshilfe SP Gynäkologie Onkologie operative Gyn./ med. Tumortherapie/ Palliativmed.

Patients are needed to participate in a clinical research study to evaluate Solid Tumor, Malignant Hematological Tumor or Primary or Secondary Prophylactic Treatment

Velbert : Fachärzte für Innere Medizin -Hämatologie und Internistische Onkologie

Patients are needed to participate in a clinical research study to evaluate Solid Tumor, Malignant Hematological Tumor or Primary or Secondary Prophylactic Treatment

Witten : FA f. Frauenheilkunde u. Geburtshilfe Marien-Hospital Witten gGmbH

Patients are needed to participate in a clinical research study to evaluate Solid Tumor, Malignant Hematological Tumor or Primary or Secondary Prophylactic Treatment

Zittau : FA für innere Medizin/Hämatologie und Int. Onkologie/Palliativmedizin

Patients are needed to participate in a clinical research study to evaluate Solid Tumor, Malignant Hematological Tumor or Primary or Secondary Prophylactic Treatment

Italy

Milano : Rhizen Trial Site

Patients are needed to participate in a clinical research study evaluating RP6530 for the treatment of Lymphoma, B-Cell or T-Cell Lymphoma

Torino : Ospedale Molinette

Patients are needed to participate in a clinical research study of OTX015 to evaluate Acute Leukemia or Other Hematological Malignacies

Japan

Fukuoka : Research site

A Phase 1 clinical study for patients with Blood Cancer or Advanced B Cell Malignancies

Isehara : Research site

A Phase 1 clinical study for patients with Blood Cancer or Advanced B Cell Malignancies

Kashiwa : National Cancer Center Hospital East

A clinical trial seeking patients for a research study of Oral azacitidine

Nagoya-shi : Research site

A Phase 1 clinical study for patients with Blood Cancer or Advanced B Cell Malignancies

Tokyo : The Cancer Institute Hospital of JFCR

A clinical trial seeking patients for a research study of Oral azacitidine

Tokyo : National Cancer Center Hospital

A clinical trial seeking patients for a research study of Oral azacitidine

Netherlands

Amsterdam : Teva Investigational Site 38045

Patients are needed to participate in a clinical research study evaluating omacetaxine mepesuccinate for the treatment of Hematologic Malignancies or Solid Tumors

Utrecht : University Medical Centre Utrecht

Patients are needed to participate in a clinical research study of Carfilzomib to evaluate Solid Tumors, Hematologic Malignancies or Hepatic Impairment

Switzerland

Bellinzona : IOSI

Patients are needed to participate in a clinical research study of OTX015 to evaluate Acute Leukemia or Other Hematological Malignacies

United Kingdom

Belfast : Northern Ireland Cancer Trials Centre - Queen's University Belfast TriaIs Centre

Patients are needed to participate in a clinical research study of Carfilzomib to evaluate Solid Tumors, Hematologic Malignancies or Hepatic Impairment

Cardlff : Velindre Hospital

Patients are needed to participate in a clinical research study of Carfilzomib to evaluate Solid Tumors, Hematologic Malignancies or Hepatic Impairment

Glasgow : Beatson West of Scotland Cancer Centre

Patients are needed to participate in a clinical research study of Carfilzomib to evaluate Solid Tumors, Hematologic Malignancies or Hepatic Impairment

Newcastle : Sir Bobby Robson Cancer Trials Research Centre

Patients are needed to participate in a clinical research study of Carfilzomib to evaluate Solid Tumors, Hematologic Malignancies or Hepatic Impairment

Stay Informed
Sign up for e-newsletters, major
events and research alerts!

3520 Lake Ave., Ste 202, Wilmette, IL 60091 | Office: 847.424.0600 | Fax: 847.424.0606 | Contact Us